Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov 14;308(18):1898-905.
doi: 10.1001/jama.2012.17304.

Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes

Affiliations

Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes

Gregory P Levin et al. JAMA. .

Abstract

Context: Lower serum 25-hydroxyvitamin D concentrations are associated with greater risks of many chronic diseases across large, prospective community-based studies. Substrate 25-hydroxyvitamin D must be converted to 1,25-dihydroxyvitamin D for full biological activity, and complex metabolic pathways suggest that interindividual variability in vitamin D metabolism may alter the clinical consequences of measured serum 25-hydroxyvitamin D.

Objective: To investigate whether common variation within genes encoding the vitamin D-binding protein, megalin, cubilin, CYP27B1, CYP24A1, and the vitamin D receptor (VDR) modify associations of low 25-hydroxyvitamin D with major clinical outcomes.

Design, setting, and participants: Examination of 141 single-nucleotide polymorphisms in a discovery cohort of 1514 white participants (who were recruited from 4 US regions) from the community-based Cardiovascular Health Study. Participants had serum 25-hydroxyvitamin D measurements in 1992-1993 and were followed up for a median of 11 years (through 2006). Replication meta-analyses were conducted across the independent, community-based US Health, Aging, and Body Composition (n = 922; follow-up: 1998-1999 through 2005), Italian Invecchiare in Chianti (n = 835; follow-up: 1998-2000 through 2006), and Swedish Uppsala Longitudinal Study of Adult Men (n = 970; follow-up: 1991-1995 through 2008) cohort studies.

Main outcome measure: Composite outcome of incident hip facture, myocardial infarction, cancer, and mortality over long-term follow-up.

Results: Interactions between 5 single-nucleotide polymorphisms and low 25-hydroxyvitamin D concentration were identified in the discovery phase and 1 involving a variant in the VDR gene replicated in independent meta-analysis. Among Cardiovascular Health Study participants, low 25-hydroxyvitamin D concentration was associated with hazard ratios for risk of the composite outcome of 1.40 (95% CI, 1.12-1.74) for those who had 1 minor allele at rs7968585 and 1.82 (95% CI, 1.31-2.54) for those with 2 minor alleles at rs7968585. In contrast, there was no evidence of an association (estimated hazard ratio, 0.93 [95% CI, 0.70-1.24]) among participants who had 0 minor alleles at this single-nucleotide polymorphism.

Conclusion: Known associations of low 25-hydroxyvitamin D with major health outcomes may vary according to common genetic differences in the vitamin D receptor.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr de Boer reported receiving research grant funding from Abbott Laboratories. Dr Houston reported pending institutional grant support from the National Institute on Aging, National Institutes of Health; and receiving payment for lectures from the American Society for Nutrition, the Department of Veteran Affairs, and Abbott Nutrition Health Institute. Dr Wang reported serving as a consultant to Diasorin; receiving an investigator-initiated grant from Diasorin; and receiving payment for lectures from Diasorin. Dr Wolf reported serving as a consultant to Abbott, Genzyme, Luitpold, Mitsubishi, Cytochroma, Astellas, and Kai; receiving institutional grants from the National Institutes of Health, Shire, and Amgen; receiving payment for lectures from Abbott, Genzyme, and Shire; and having a pending patent. Dr Psaty reported serving on a data and safety monitoring board for a clinical trial of a device funded by Zoll ZifeCor; and serving on a steering committee for the Yale Open Data Access Project funded by Medtronic. Dr Kestenbaum reported receiving institutional grant support from Amgen. No other authors reported disclosures.

Comment in

Similar articles

Cited by

References

    1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281. - PubMed
    1. Rosen CJ. Clinical practice: vitamin D insufficiency. N Engl J Med. 2011;364(3):248–254. - PubMed
    1. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168(11):1174–1180. - PMC - PubMed
    1. Melamed ML, Michos ED, Post W, Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629–1637. - PMC - PubMed
    1. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168 (12):1340–1349. - PubMed

Publication types

MeSH terms

Substances

Grants and funding